Fig. 1From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistanceEstimated Weibull survival curves for cabazitaxel group (a) and ASTI group (b). PFS, progression-free survival; OS, overall survival; ASTI, androgen-signaling-targeted inhibitorBack to article page